Acinar cell NLRP3 inflammasome and gasdermin D (GSDMD) activation mediates pyroptosis and systemic inflammation in acute pancreatitis
Lin Gao, Xiaowu Dong, Weijuan Gong, Wei Huang, Jing Xue, Qingtian Zhu, Nan Ma, Weiwei Chen, Xianghui Fu, Xiang Gao, Zhaoyu Lin, Yanbing Ding, Juanjuan Shi, Zhihui Tong, Tingting Liu, Rajarshi Mukherjee, Robert Sutton, Guotao Lu, Weiqin Li
Abstract
Background and Purpose Pyroptosis is a lytic form of pro‐inflammatory cell death characterised as caspase 1 dependent with canonical NLRP3 inflammasome‐induced gasdermin D (GSDMD) activation. We aimed to investigate the role of acinar pyroptotic cell death in pancreatic injury and systemic inflammation in AP. Experimental Approach Pancreatic acinar pyroptotic cell death pathway activation upon pancreatic toxin stimulation in vitro and in vivo was investigated. Effects of pharmacological (NLRP3 and caspase‐1 inhibitors), constitutive ( Nlrp3 −/− , Casp1 −/− and Gsdmd −/− ) and acinar cell conditional ( Pdx1 Cre Nlrp3 Δ/Δ and Pdx1 Cre Gsdmd Δ/Δ ) genetic inhibition on pyroptotic acinar cell death, pancreatic necrosis and systemic inflammation were assessed using mouse AP models (caerulein, sodium taurocholate and l ‐arginine). Effects of Pdx1 Cre Gsdmd Δ/Δ versus myeloid conditional knockout ( Lyz2 Cre Gsdmd Δ/Δ ) and Gsdmd −/− versus receptor‐interacting protein 3 (RIP3) inhibitor were compared in CER‐AP. Key Results There was consistent pyroptotic acinar cell death upon pancreatic toxin stimulation both in vitro and in vivo , which was significantly reduced by pharmacological or genetic pyroptosis inhibition. Pdx1 Cre Gsdmd Δ/Δ but not Lyz2 Cre Gsdmd Δ/Δ mice showed significantly reduced pyroptotic acinar cell death , pancreatic necrosis and systemic inflammation in caerulein‐AP. Co‐application of RIP3 inhibitor on Gsdmd −/− mice further increased protection on caerulein‐AP. Conclusion and Implications This work demonstrates a critical role for NLRP3 inflammasome and GSDMD activation‐mediated pyroptosis in acinar cells, linking pancreatic necrosis and systemic inflammation in AP. Targeting pyroptosis signalling pathways holds promise for specific AP therapy.